ABSTRACT
Objective To assess the efficacy and safety of polyherbal formulation (designated as IP) in comparison to placebo as add on to the standard of care (SoC) among patients with mild to moderate novel corona virus disease 2019 (COVID-19)
Methods Laboratory proved patients of mild to moderate COVID-19 disease were randomized to either placebo or IP as an add-on to SoC. Using quantitative reverse transcription-polymerase chain reaction (qRTPCR), we assessed the effect on viral load (VL). Change in immunological parameters such as blood lymphocyte subset, serum immunoglobulin was determined. The clinical improvement was assessed using a numerical rating scale (NRS) and WHO ordinal scale. Patients were followed for 30 days after randomization.
Results In total, 72 patients were randomized to either placebo (n=33) and IP (n=39). Fifty-two patients (n=21 in placebo and n=31 in IP arm) had qRT-PCR on day 0 and day 4. There was significant reduction in VL in IP arm (from 662081 copies/mL on day 0 to 48963 copies/mL on day 4; p=0.002)) but not in the placebo arm (from 385670 copies/mL on day 0 to 66845 copies/mL on day 4, p=0.106). Change in the NRS score and WHO ordinal scale score was significant in both treatment arms. However, the difference between the two groups was statistically significant in favour of drug group,. The increase in Th1 response was significant in the IP arm (p=0.023) but not in the placebo arm (p=0.098), thus implying immunomodulatory activity in the drug. No safety concerns were observed in any of the trial participants.
Conclusion This study finds that polyherbal formulation reduces viral load and contributes to immunomodulation and improvement in clinical conditions when used as add-on to the standard care in patients with mild to moderate COVID-19 without any side effects. These findings need to be further confirmed in a large, prospective, randomized study.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Clinical Trials Registry - India (ICMR-NIMS) CTRI/2020/07/026570 http://ctri.nic.in/Clinicaltrials/rmaindet.php?trialid=45007&EncHid=44666.83749&modid=1&compid=19 Clinical Trials Registry - India (ICMR-NIMS) CTRI/2020/07/026570 http://ctri.nic.in/Clinicaltrials/rmaindet.php?trialid=45007&EncHid=44666.83749&modid=1&compid=19
Clinical Protocols
https://doi.org/10.1186/s13063-020-04906-x
Funding Statement
This work was funded by AMAI Charitable Trust Pune. The funders had no role in study design, data collection and analysis. While played role in decision to publish, or preparation of the manuscript. https://www.nhp.gov.in/hospital/amai-charitable-trust-institute-of-urology-pune-maharashtra
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study was approved by PCMCs PGI YCMH Ethics Committee with number YCMH/WS/5/KV/705/2020 (PDF copy of the Ethics Committtee approval letter has mentioned hereunder is attached as a Supplemental file) Project title: Study/Protocol No -CoviQuest-01 The Study/Protocol was reviewed and approved: The following members of the Institutional Ethics committee (IEC) were present at the meeting held on Date 09.06.2020 Sr.No./Name of member/Position on IEC/Affiliation/Gender 1. Dr. Abhijeet Tilak, Chairman, Not Affiliated, Male 2. Dr. Tushar Patil, Member Secretary, Affiliated,Male 3. Dr. Sanjay Juvekar, Social Scientist, Not Affiliated, Male 4. Dr. Maroti Gaikwad, Clinician, Affiliated, Male 5. Dr. Deepali Ambike, Clinician, Affiliated, Female 6. Mr. Chandrakant Indalkar, Legal Expert, Not Affiliated Male 7. Dr. Mangal Supe, Clinician, Affiliated,Female 8. Mr. Dnyaneshwar Shinde, Lay Person, Not AffiliatedMale 9. Dr. Pravin N. Soni, Clinician, Affiliated, Male 10. Dr. Vaishali Bhamre, Independent Consultant, Expert, Not Affiliated, Female The trial is approved in its presented form. The approval is valid until one year or duration of project whichever is later from the date of sanction. Dr. Abhijeet Tilak Chairman IEC PCMCs PGI, YCMH ECR/1236/Inst/MH/2019 Date 12. 06 .2020 Name - Dr. Tushar V. Patil. Member Secretary, IEC, PCMCs PGI, YCMH ECR/1236/Inst/MH/2019 Date 12. 06 .2020
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
h.rangnekar{at}questclinicalservices.co.in dr.rangnekar{at}gmail.com
kalpanajoshi1788{at}gmail.com
drkishorsuryawanshi{at}gmail.com
drpravinsoni18{at}gmail.com
drpatankar02{at}yahoo.in
sktejas09{at}gmail.com
sagarpatankar87{at}gmail.com
drdjha{at}gmail.com
researchace2{at}gmail.com
Data Availability
Data cannot be shared publicly because the organization is a semi government institution and access to the clinical records is restricted. This data are available from the Institutional Data Access upon requesting Dr. Pravin Soni(M.D (Gen.Med), HoD Dept of Med.)(Email-drpravinsoni18{at}gmail.com) for researchers who meet the criteria for access to confidential data. Data on investigations like viral load and few haematological investigations can be made available without any restrictions.
